Open AccessOutcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis
Author(s) -
Andrew Rosenbaum,
Omar F. AbouEzzeddine,
Martha Grogan,
Angela Dispenzieri,
Sudhir S. Kushwaha,
Alfredo L. Clavell,
Richard C. Daly,
Brooks S. Edwards
Publication year - 2018
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002240
Subject(s) - transthyretin , medicine , ejection fraction , cardiology , cardiac amyloidosis , heart failure , amyloidosis , cohort , heart transplantation
The true prevalence of heart failure due to wild type transthyretin amyloidosis (ATTRwt) is likely underestimated. There is a paucity of data with regard to the management of ATTRwt-related advanced heart failure and the natural history of extracardiac ATTRwt.